Prostatype Genomics AB Total Liabilities
Prostatype Genomics AB total liabilities. Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has total liabilities worth Skr7.36 Million SEK (≈ $791.62K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PROGEN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Prostatype Genomics AB (2015–2024)
Total liabilities of Prostatype Genomics AB from 2015 to 2024. This chart illustrates how Prostatype Genomics AB's total liabilities have evolved over time, based on quarterly financial data.
Prostatype Genomics AB Competitors by Total Liabilities
The table below lists competitors of Prostatype Genomics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Creo Medical Group PLC
LSE:CREO
|
UK | GBX9.10 Million |
|
Fort St James Nickel Corp
V:FTJ
|
Canada | CA$2.11 Million |
|
GenixPharmaceucticals Corporation
V:GENX
|
Canada | CA$1.58 Million |
|
GOLDSTONE RES LTD. LS-01
F:GVL1
|
Germany | €13.63 Million |
|
VSee Health, Inc.
NASDAQ:VSEE
|
USA | $16.96 Million |
|
Gemfields Plc
LSE:GEM
|
UK | GBX206.14 Million |
|
Real Estate Investors PLC
LSE:RLE
|
UK | GBX35.28 Million |
|
Tinybuild Inc
LSE:TBLD
|
UK | GBX11.51 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Prostatype Genomics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Prostatype Genomics AB (PROGEN) total assets.
Liquidity & Leverage Metrics
Prostatype Genomics AB Total Liabilities Ratios Explained
Prostatype Genomics AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prostatype Genomics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prostatype Genomics AB (2015–2024)
The table below shows the annual total liabilities of Prostatype Genomics AB from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr8.50 Million ≈ $914.84K |
-65.37% |
| 2023-12-31 | Skr24.55 Million ≈ $2.64 Million |
+411.52% |
| 2022-12-31 | Skr4.80 Million ≈ $516.45K |
+11.68% |
| 2021-12-31 | Skr4.30 Million ≈ $462.42K |
-20.02% |
| 2020-12-31 | Skr5.37 Million ≈ $578.15K |
-40.49% |
| 2018-12-31 | Skr9.03 Million ≈ $971.49K |
-33.07% |
| 2017-12-31 | Skr13.49 Million ≈ $1.45 Million |
+181.80% |
| 2016-12-31 | Skr4.79 Million ≈ $515.11K |
-12.42% |
| 2015-12-31 | Skr5.47 Million ≈ $588.18K |
-- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more